Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial.


Journal

The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683

Informations de publication

Date de publication:
02 2019
Historique:
received: 13 09 2018
revised: 12 10 2018
accepted: 23 10 2018
pubmed: 7 12 2018
medline: 6 5 2020
entrez: 4 12 2018
Statut: ppublish

Résumé

Screening flexible sigmoidoscopy reduces incidence and mortality of colorectal cancer. Previously reported results from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial had a median follow-up of 12 years. Whether the benefit is sustained over the long term and remains so in both sexes and all age groups is uncertain. We report long-term results after an additional 5 years of follow-up. Participants in the PLCO trial were recruited from the general population in the catchment areas of ten screening centres across the USA, without previous diagnosis of a prostate, lung, colorectal, or ovarian cancer or current cancer treatment. From 1993 to 2001, participants aged 55-74 years were randomly assigned to usual care or flexible sigmoidoscopy at baseline and again at 3 years or 5 years. Randomisation was done within blocks and stratified by centre, age, and sex. The primary endpoint was cause-specific mortality and secondary endpoints included incidence and tumour staging; cause of death was determined without knowledge of study arm. In this analysis, we assessed incidence and mortality rates overall, by time-period, and by combinations of sex, age at baseline (55-64 years/65-74 years), location (distal/proximal), and stage, on an intent-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00002540. After a median follow-up of 15·8 years (IQR 13·2-18·0) for incidence and 16·8 years (14·4-18·9) for mortality, the incidence of colorectal cancer was significantly lower in the intervention arm (1461 cases; 12·55 per 10 000 person-years) than with usual care (1761 cases; 15·33 per 10 000 person-years; relative risk [RR] 0·82, 95% CI 0·76-0·88). Similarly, mortality was lower in the intervention arm (417 deaths; 3·37 per 10 000 person-years) than the usual care arm (549; 4·48 per 10 000 person-years; RR 0·75, 95% CI 0·66-0·85). The reduction in mortality was limited to the distal colon, with no significant effect in the proximal colon. Reductions in incidence were significantly larger in men than women (p Reductions in colorectal cancer incidence and mortality from flexible sigmoidoscopy screening are sustained over the long term. Differences by sex and age should be examined in other ongoing trials of colorectal cancer screening to help clarify if different screening strategies would achieve greater risk reduction. Extended follow-up was funded under NIH contract HHSN261201600007I.

Sections du résumé

BACKGROUND
Screening flexible sigmoidoscopy reduces incidence and mortality of colorectal cancer. Previously reported results from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial had a median follow-up of 12 years. Whether the benefit is sustained over the long term and remains so in both sexes and all age groups is uncertain. We report long-term results after an additional 5 years of follow-up.
METHODS
Participants in the PLCO trial were recruited from the general population in the catchment areas of ten screening centres across the USA, without previous diagnosis of a prostate, lung, colorectal, or ovarian cancer or current cancer treatment. From 1993 to 2001, participants aged 55-74 years were randomly assigned to usual care or flexible sigmoidoscopy at baseline and again at 3 years or 5 years. Randomisation was done within blocks and stratified by centre, age, and sex. The primary endpoint was cause-specific mortality and secondary endpoints included incidence and tumour staging; cause of death was determined without knowledge of study arm. In this analysis, we assessed incidence and mortality rates overall, by time-period, and by combinations of sex, age at baseline (55-64 years/65-74 years), location (distal/proximal), and stage, on an intent-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00002540.
FINDINGS
After a median follow-up of 15·8 years (IQR 13·2-18·0) for incidence and 16·8 years (14·4-18·9) for mortality, the incidence of colorectal cancer was significantly lower in the intervention arm (1461 cases; 12·55 per 10 000 person-years) than with usual care (1761 cases; 15·33 per 10 000 person-years; relative risk [RR] 0·82, 95% CI 0·76-0·88). Similarly, mortality was lower in the intervention arm (417 deaths; 3·37 per 10 000 person-years) than the usual care arm (549; 4·48 per 10 000 person-years; RR 0·75, 95% CI 0·66-0·85). The reduction in mortality was limited to the distal colon, with no significant effect in the proximal colon. Reductions in incidence were significantly larger in men than women (p
INTERPRETATION
Reductions in colorectal cancer incidence and mortality from flexible sigmoidoscopy screening are sustained over the long term. Differences by sex and age should be examined in other ongoing trials of colorectal cancer screening to help clarify if different screening strategies would achieve greater risk reduction.
FUNDING
Extended follow-up was funded under NIH contract HHSN261201600007I.

Identifiants

pubmed: 30502933
pii: S2468-1253(18)30358-3
doi: 10.1016/S2468-1253(18)30358-3
pmc: PMC6335177
mid: NIHMS1516009
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT00002540']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101-110

Subventions

Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S
pubmed: 11189684
N Engl J Med. 2005 May 19;352(20):2061-8
pubmed: 15901859
Cancer. 2010 Feb 1;116(3):544-73
pubmed: 19998273
Clin Trials. 2010 Feb;7(1):69-77
pubmed: 20156958
BMJ. 2010 Aug 24;341:c4618
pubmed: 20736284
J Natl Cancer Inst. 2011 Sep 7;103(17):1310-22
pubmed: 21852264
Scand J Gastroenterol. 2012 Feb;47(2):184-90
pubmed: 22229966
J Natl Cancer Inst. 2012 Feb 22;104(4):280-9
pubmed: 22298838
N Engl J Med. 2012 Feb 23;366(8):697-706
pubmed: 22356323
N Engl J Med. 2012 Jun 21;366(25):2345-57
pubmed: 22612596
Endoscopy. 2012 Jul;44(7):695-702
pubmed: 22723185
N Engl J Med. 2013 Sep 19;369(12):1095-105
pubmed: 24047059
JAMA. 2014 Aug 13;312(6):606-15
pubmed: 25117129
Gut. 2015 Jun;64(6):982-90
pubmed: 25804631
Rev Recent Clin Trials. 2015;10(3):206-11
pubmed: 26238119
Rev Recent Clin Trials. 2015;10(3):187-93
pubmed: 26435288
JAMA Intern Med. 2016 Jul 1;176(7):894-902
pubmed: 27214731
Cancer Epidemiol. 2016 Dec;45:26-31
pubmed: 27687075
BMJ. 2017 Jan 13;356:i6673
pubmed: 28087510
Lancet. 2017 Apr 1;389(10076):1299-1311
pubmed: 28236467
Am J Gastroenterol. 2017 Nov;112(11):1736-1746
pubmed: 29016565
Rev Recent Clin Trials. 2018;13(4):257-273
pubmed: 29629665
Ann Intern Med. 2018 Jun 5;168(11):775-782
pubmed: 29710125
CA Cancer J Clin. 2018 Jul;68(4):250-281
pubmed: 29846947

Auteurs

Eric A Miller (EA)

National Cancer Institute, Division of Cancer Prevention, Rockville, MD, USA. Electronic address: eric.miller2@nih.gov.

Paul F Pinsky (PF)

National Cancer Institute, Division of Cancer Prevention, Rockville, MD, USA.

Robert E Schoen (RE)

University of Pittsburgh, Department of Medicine and Epidemiology, Pittsburgh, PA, USA.

Philip C Prorok (PC)

National Cancer Institute, Division of Cancer Prevention, Rockville, MD, USA.

Timothy R Church (TR)

University of Minnesota, School of Public Health, Minneapolis, MN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH